Kentaro Ito

Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer

Yuta Adachi, Kentaro Ito, Yuko Hayashi et al. · Clinical Cancer Research · 2020 · 239 citations

Medicine, Oncology, Pharmacology +16

A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L)

Hiroyuki Yamaguchi, Kazushige Wakuda, Minoru Fukuda et al. · Journal of Thoracic Oncology · 2021 · 71 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L

Shinya Sakata, Kohei Otsubo, Hisako Yoshida et al. · Cancer Science · 2021 · 71 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Sequential Therapy with Crizotinib and Alectinib in ALK -Rearranged Non–Small Cell Lung Cancer—A Multicenter Retrospective Study

Kentaro Ito, Osamu Hataji, Hiroyasu Kobayashi et al. · Journal of Thoracic Oncology · 2016 · 57 citations · Full text

Medicine, Oncology, Pharmacology +12

Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria

Tadashi Sakaguchi, Kentaro Ito, Kazuki Furuhashi et al. · Respiratory Investigation · 2019 · 47 citations

Medicine, Oncology, Chemotherapy +7